Takezawa Yuta, Yaegashi Hiroshi, Iijima Masashi, Kawaguchi Shohei, Nohara Takahiro, Shigehara Kazuyoshi, Izumi Kouji, Kadono Yoshihumi, Ikeda Hiroko, Mizokami Atsushi
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa 920-8641, Japan.
Department of Urology, Kouseiren Takaoka Hospital, Takaoka, Toyama 933-8555, Japan.
Mol Clin Oncol. 2021 Mar;14(3):48. doi: 10.3892/mco.2021.2210. Epub 2021 Jan 19.
Germ cell tumors with somatic-type malignancy (GCTSTM) are rare, and patients with GCTSTM have extremely poor prognoses with a median survival of nine months. Somatic-type malignancy, which are mainly sarcomas, usually exhibit chemoresistance. The recommended therapy for GCTSTM is radical resection; however, Pazopanib, which is a multityrosine kinase inhibitor, has indicated therapeutic effects for some soft tissue sarcoma components. The current study reports the case of a 21-year-old Asian man who presented with GCTSTM after combined chemotherapy for a primary mediastinal germ cell tumor with multiple lung metastases. Despite the metastases, his disease was stable after continuous administration of Pazopanib for two years and then stopping the medication for four years. To the best of our knowledge, the current report is the first report of a durable response by Pazopanib for GCTSTM, which is a rare outcome.
伴有体细胞型恶性肿瘤的生殖细胞肿瘤（GCTSTM）较为罕见，GCTSTM患者的预后极差，中位生存期为9个月。体细胞型恶性肿瘤主要为肉瘤，通常表现出化疗耐药性。GCTSTM的推荐治疗方法是根治性切除；然而，帕唑帕尼作为一种多酪氨酸激酶抑制剂，已显示出对某些软组织肉瘤成分的治疗效果。本研究报告了一名21岁亚洲男性的病例，该患者在对原发性纵隔生殖细胞肿瘤伴多发肺转移进行联合化疗后出现了GCTSTM。尽管存在转移，但在连续服用帕唑帕尼两年然后停药四年后，他的病情保持稳定。据我们所知，本报告是帕唑帕尼对GCTSTM产生持久反应的首例报告，这是一种罕见的结果。
